1. Academic Validation
  2. Discovery of SD-965 as a Potent, Selective, and Efficacious STAT3 PROTAC Degrader

Discovery of SD-965 as a Potent, Selective, and Efficacious STAT3 PROTAC Degrader

  • J Med Chem. 2026 Apr 9;69(7):8364-8387. doi: 10.1021/acs.jmedchem.5c03767.
Dimin Wu 1 Haibin Zhou 1 Longchuan Bai 1 Ranjan Kumar Acharyya 1 Hoda Metwally 1 Donna McEachern 1 Mi Wang 1 Jelena Tošović 1 Rohan Kalyan Rej 1 Meilin Wang 2 Bo Wen 2 Duxin Sun 2 Shaomeng Wang 1 3 4 5
Affiliations

Affiliations

  • 1 Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, Michigan 48109, United States.
  • 2 Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States.
  • 3 Department of Pharmacology, University of Michigan, Ann Arbor, Michigan 48109, United States.
  • 4 Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States.
  • 5 The Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan 48109, United States.
Abstract

Signal transducer and activator of transcription 3 (STAT3) is a promising therapeutic target for human cancers and Other human diseases. Herein, we report on the design, synthesis, and evaluation of novel STAT3 PROTAC degraders using high-affinity STAT3 ligands and Cereblon ligands. Our study led to the discovery of SD-965 as a potent, selective, and efficacious STAT3 Degrader. A single intravenous administration of SD-965 effectively induces rapid, complete, and durable depletion of STAT3 protein in mouse native and human xenograft tumor tissues with no depletion of Other STAT proteins. SD-965 is capable of achieving tumor regression even with weekly administration in human leukemia and lymphoma xenograft models in mice without any signs of toxicity. SD-965 represents a promising STAT3 Degrader for extensive evaluation for the treatment of human cancers and Other human diseases.

Figures
Products